<DOC>
	<DOCNO>NCT02647320</DOCNO>
	<brief_summary>The hypothesis Phase 2 , 12-week study , DS-8500a improve glycemic control relative placebo , base change HbA1c , acceptable safety tolerability , patient Type 2 Diabetes Mellitus ( T2DM ) treat metformin .</brief_summary>
	<brief_title>12-Week Study DS-8500a Subjects With Type 2 Diabetes Mellitus Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Able provide write informed consent adhere study visit schedule treatment Diagnosed Type 2 diabetes mellitus define American Diabetes Association Standards Medical Care Diabetes 2015 Male female ≥ 18 ≤ 70 year age Screening fast Cpeptide &gt; 0.5 ng/mL Women child bear potential ( WOCBP ) must willing use doublebarrier contraception entire study WOCBP must negative pregnancy test ( human chorionic gonadotropin , beta subunit [ βhCG ] ) enter Leadin Period Body mass index ≥ 25 kg/m2 ≤ 45 kg/m2 Screening Visit On stable ( ≥ 8 week ) metformin monotherapy ≥ 1000 mg/day Screening HbA1c ≥ 7.0 % ≤ 10 % Taking ≥ 80 % ≤ 120 % dispensed DS8500a placebo tablet sitagliptin placebo capsule Leadin Period History type 1 diabetes and/or history ketoacidosis History insulin use &gt; 2 week within 2 month prior Screening Visit Two reading fast Selfmonitoring Blood Glucose ( SMBG ) &gt; 240 mg/dL worsening symptom hyperglycemia one SMBG level &gt; 240 mg/dL second week Leadin Period , confirm laboratory measurement Screening hemoglobin &lt; 12 g/dL male &lt; 11 g/dL female Blood donation within 2 month prior Screening Visit plan donate blood blood product study Subjects bariatric surgery gastric bypass Screening thyroid stimulate hormone ( TSH ) level within normal range ( base reference laboratory value ) Screening Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &gt; 2.0 x upper limit normal ( ULN ) , and/or total bilirubin &gt; 1.5 x ULN . If subject total bilirubin &gt; 1.5 ULN , unconjugated conjugated bilirubin fraction analyze subject document Gilbert 's syndrome may enrol Screening Serum creatinine ≥ 1.5 mg/dL male ≥ 1.4 mg/dL female , creatinine clearance ( CrCl ) &lt; 50 mL/min male females Screening Creatine kinase ( CK ) &gt; 3.0 × ULN History unstable angina , myocardial infarction , cerebrovascular accident , transient ischemic attack , peripheral arterial event revascularization procedure 6 month prior Screening Visit plan vascular procedure surgery study period History congestive heart failure ( CHF ) Exclusionary concomitant medication : . Eight week prior screen throughout duration study : Any diabetes medication metformin ; prescription counter medication weightloss . Systemic corticosteroid ( include nasal inhale ) , exception use topical ophthalmic corticosteroid . Rosuvastatin &gt; 20 mg daily . b . During treatment period , additional medication prohibit base potential drugdrug interaction ( DDI ) ( see Section 5.6 ) Subjects anticipate interruption metformin study drug use course clinical trial ( e.g. , due image procedure involve iodinate contrast medium ) Subjects treatment sitagliptin 100 mg contraindicate ( e.g. , know hypersensitivity intolerance sitagliptin ) may medically advisable ( e.g. , history pancreatitis ) Abuse dependence prescription medication , illicit drug , alcohol within last 1 year Any history malignancy basal cell carcinoma within past 5 year Pregnancy breastfeeding , intent become pregnant study period Known ( evidence ) infection human immunodeficiency virus Any condition , laboratory abnormality , concomitant therapy , opinion Investigator , might pose risk subject make participation subject 's best interest Subject currently enrol yet complete least 30 day since end another investigational device drug study receive investigational agent A direct familial relationship Sponsor , Investigator , site personnel affiliate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>interventional</keyword>
	<keyword>double blind</keyword>
	<keyword>phase 2</keyword>
</DOC>